แนวคิดหลัก
Weight loss significantly improves outcomes in HFpEF patients.
บทคัดย่อ
The STEP-HFpEF trial analyzed the impact of weight loss on outcomes in patients receiving weekly semaglutide treatment. Weight loss was found to be a major factor in improving symptoms, physical limitations, exercise capacity, and inflammation. The study highlighted the importance of medically induced weight loss in managing patients with obesity-phenotype HFpEF. Key findings included significant improvements in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, 6-minute walk distance, and C-reactive protein levels with weight loss. The study also indicated that weight loss was a good surrogate marker for the range of effects from treatment with semaglutide, a GLP-1 receptor agonist.
สถิติ
Weight loss by itself was a major reason why the treatment improved outcomes.
A 16.1-point improvement in KCCQ score for 5%-10% weight loss.
A 21.6-point improvement in KCCQ score for at least 20% weight loss.
Every 10% drop in body weight was linked with improvements in KCCQ score, walk distance, and CRP levels.
คำพูด
"The more weight a person lost, the more benefit they got." - Dr. Mikhail Kosiborod
"At least 75% of the effect was due to weight loss." - Dr. Naveed Sattar